Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
Does Biogen's Recent Win Make It a Must-Buy Stock?
09:56am, Wednesday, 12'th Oct 2022 The Motley Fool
Will Biogen investors be let down again, or is this the real deal?
4 Biotech Stocks With Huge Incoming Catalysts
09:29am, Wednesday, 12'th Oct 2022 The Motley Fool
All four of these drugmakers are expecting important FDA approval decisions over the next few months.
Does Biogen's Recent Win Make It a Must-Buy Stock?
05:56am, Wednesday, 12'th Oct 2022
Will Biogen investors be let down again, or is this the real deal?
4 Biotech Stocks With Huge Incoming Catalysts
05:29am, Wednesday, 12'th Oct 2022
All four of these drugmakers are expecting important FDA approval decisions over the next few months.
Biogen Inc. (BIIB) Stock Moves -0.28%: What You Should Know
09:50pm, Tuesday, 11'th Oct 2022 Zacks Investment Research
Biogen Inc. (BIIB) closed at $254.07 in the latest trading session, marking a -0.28% move from the prior day.
Jim Cramer goes over the best and worst Q3 performers in the S&P 500
06:38pm, Tuesday, 11'th Oct 2022
Cramer said he wouldn't touch this stock with a 10 foot pole.
These Are The Five Best And Worst Performing Large-Cap Stocks In September 2022
07:57pm, Monday, 10'th Oct 2022
September has been a tough month for the U.S. stock market historically, and this year was no different.
Despite Advancement, Benefits From Alzheimer's Drugs May Be Limited, Say Researchers
07:14pm, Monday, 10'th Oct 2022 Benzinga
Recently, Biogen Inc (NASDAQ: BIIB) and Eisai Co (OTC: ESALY) announced encouraging data from the most-watched Alzheimer's therapies in the clinic.
Lecanemab cleared accumulations in the brain of
These 7 Biotech Stocks Are Set to Boom in 2023
06:15am, Monday, 10'th Oct 2022
Among biotech stocks, there are several established names that have products in markets and deep pipelines. These companies deliver predictable revenue and earnings, and maybe even a dividend for good
Annovis (ANVS) Gains on FDA Authorization for AD Study
04:57pm, Friday, 07'th Oct 2022 Zacks Investment Research
Annovis (ANVS) shares jump following the FDA's authorization to proceed with the phase II/III clinical study of lead candidate buntanetap in moderate Alzheimer's Disease (AD).
Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2022
02:03pm, Friday, 07'th Oct 2022 Benzinga
Upgrades
For Federal Signal Corp (NYSE:FSS), DA Davidson upgraded the previous rating of Neutral to Buy. In the second quarter, Federal Signal showed an EPS of $0.53, compared to $0.50 from the year-a
3 Alzheimer Stocks To Buy As The Race For A Cure Heats Up
09:29am, Friday, 07'th Oct 2022 Investing.comBest ETFs Get Harder To Find In September
07:00am, Friday, 07'th Oct 2022
Some of the best ETFs and mutual funds continued their downward spiral as the slaughter in the markets continued in September. The post Best ETFs Get Harder To Find In September appeared first on Inve
Is This Stock a Buy After Soaring by 37%?
01:30pm, Thursday, 06'th Oct 2022 The Motley Fool
Don't press the buy button too fast.
Zacks Market Edge Highlights: ExxonMobil, Meta Platforms, UnitedHealth Group, Biogen and NVIDIA
11:30am, Thursday, 06'th Oct 2022 Zacks Investment Research
ExxonMobil, Meta Platforms, UnitedHealth Group, Biogen and NVIDIA are part of the Zacks Market Edge article.
